ReviewMicroorganisms2021
COVID-19: Insights into Potential Vaccines.
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 56 citations in OpenAlex.
- Safety of COVID-19 vaccines.Journal of medical virology · 2021Trial
- Long-term kinetics of anti-RBD IgG antibodies 16 months after COVID-19 vaccination in Morocco: a longitudinal cohort study.Scientific reports · 2026Article
- Analysis of ethical considerations of COVID‑19 vaccination: lessons for future.BMC medical ethics · 2023Article
- An update on vaccine status and the role of nanomedicine against SARS-CoV-2: A narrative review.Health science reports · 2023Article
- Special Issue "SARS-CoV-2: Epidemiology and Pathogenesis": Editorial.Microorganisms · 2023Article
- Article
- BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure.Medicina (Kaunas, Lithuania) · 2022Article
- Chest HRCT Assessment of COVID-19 Patients in Vaccinated versus Nonvaccinated Patients: A Comparative Study in a Tertiary Care Hospital.The Indian journal of radiology & imaging · 2022Article
- A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens.Pharmaceutical research · 2022Review
- SARS-CoV-2 variants and vulnerability at the global level.Journal of medical virology · 2022Review
- CGRP-monoclonal antibodies and SARS-CoV-2 vaccination.Journal of neurology · 2022Article
- Photonics enabled intelligence system to identify SARS-CoV 2 mutations.Applied microbiology and biotechnology · 2022Review
- A global survey in the developmental landscape of possible vaccination strategies for COVID-19.Clinical immunology (Orlando, Fla.) · 2022Review
- Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic.Osong public health and research perspectives · 2022Article
- Lymphadenopathy subsequent to Covishield (ChAdOx1 nCoV-19) Corona virus vaccine: ultrasound findings and clinical implications.Therapeutic advances in vaccines and immunotherapy · 2022Article
- Cross-species virus transmission and its pandemic potential.Bulletin of the National Research Centre · 2022Review
- Article
- The Impact of Vaccination Against SARS-CoV-2 Virus on the Outcome of COVID-19 Disease.Infection and drug resistance · 2022Article
- Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges.Biomedicines · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to develop an effective vaccine to protect against COVID-19. Researchers have developed various types of candidate vaccines with the release of the genetic sequence of the SARS-CoV-2 virus in January. These include inactivated viral vaccines, protein subunit vaccines, mRNA vaccines, and recombinant viral vector vaccines. To date, several vaccines have been authorized for emergency use and they have been administered in countries across the globe. Meanwhile, there are also vaccine candidates in Phase III clinical trials awaiting results and approval from authorities. These candidates have shown positive results in the previous stages of the trials, whereby they could induce an immune response with minimal side effects in the participants. This review aims to discuss the different vaccine platforms and the clinical trials of the candidate vaccines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.